Gilead Sciences (Gilead Sciences) Interest Expense : $-944 Mil (TTM As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Gilead Sciences Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Gilead Sciences's interest expense for the three months ended in Dec. 2023 was $ -252 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-944 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Gilead Sciences's Operating Income for the three months ended in Dec. 2023 was $ 2,008 Mil. Gilead Sciences's Interest Expense for the three months ended in Dec. 2023 was $ -252 Mil. Gilead Sciences's Interest Coverage for the quarter that ended in Dec. 2023 was 7.97. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gilead Sciences Interest Expense Historical Data

The historical data trend for Gilead Sciences's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences Interest Expense Chart

Gilead Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-995.00

-984.00

-1,001.00

-935.00

-944.00

Gilead Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-226.00	-230.00	-230.00	-232.00	-252.00

Gilead Sciences Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-944 Mil.

Gilead Sciences (NAS:GILD) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Gilead Sciences's Interest Expense for the three months ended in Dec. 2023 was $-252 Mil. Its Operating Income for the three months ended in Dec. 2023 was $2,008 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $23,189 Mil.

Gilead Sciences's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	2008	/	-252
	=	7.97

The higher the ratio, the stronger the company's financial strength is.

Gilead Sciences (Gilead Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (NAS:GILD) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

GILD:Mexico GILD:Italy GISd:UK 0QYQ:UK GIS:Germany GIS:Germany GIS:Germany GIS:Germany GILD34:Brazil GILD:Austria GILD:Argentina

Address

333 Lakeside Drive, Foster, CA, USA, 94404

Website

https://www.gilead.com

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Executives

Andrew D Dickinson	officer: EVP, Chief Financial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Johanna Mercier	officer: Chief Commercial Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Merdad Parsey	officer: Chief Medical Officer	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Patterson	officer: SVP, Controllership	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Diane E. Wilfong	officer: SVP, Controller & CAO	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Deborah H Telman	officer: EVP, Corporate Affairs & GC	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Brett A Pletcher	officer: EVP, Gen Counsel & Corp Sec	333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Jeffrey Bluestone	director	C/O PROVENTION BIO, INC., P.O. BOX 666, OLDWICK NJ 08858
Anthony Welters	director
Javier Rodriguez	director	601 HAWAII ST., EL SEGUNDO CA 90245
John Francis Cogan	director	2010 NORTH FIRST STREET, SUITE 310, SAN JOSE CA 95131
Gayle E Wilson	director	C/O GILEAD SCIENCES, INC., 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Olsen Per Wold	director	C/O GILEAD SCIENCES, 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Sandra Horning	director	333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Richard James Whitley	director	UAB, CHB 303, 1600 7TH AVENUE SOUTH, BIRMINGHAM AL 35233-1711